Thrombotic thrombocytopenic purpura diagnostic study of choice: Difference between revisions
Shyam Patel (talk | contribs) |
|||
| (7 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{CMG}} | __NOTOC__ | ||
{{Thrombotic thrombocytopenic purpura}} | |||
{{CMG}} {{AE}} {{Saeedeh}},{{S.G.}} | |||
== Overview == | == Overview == | ||
== Study of choice == | == Study of choice == | ||
* Complete blood count (CBC) with platelet count | * '''ADAMTS13 test:''' | ||
'''Studies that may be considered for diagnosis of the suspected cases of TTP:''' | |||
* [[Complete blood count]] ([[Complete blood count|CBC]]) with [[platelet]] count | |||
* Review of the peripheral blood smear | * Review of the peripheral blood smear | ||
* Serum electrolytes and creatinine | * Serum electrolytes and creatinine | ||
| Line 12: | Line 16: | ||
* ADAMTS13 activity and inhibitor testing | * ADAMTS13 activity and inhibitor testing | ||
* Stool exam | * Stool exam | ||
* Genetic testing for mutation in ADAMTS13 at the genomic level | |||
* Antibodies to complement factors H and I for ruling out atypical hemolytic uremic syndrome | |||
<br> | <br> | ||
==PLASMIC score == | ==PLASMIC score == | ||
{{#Widget:PLASMIC score}} | {{#Widget:PLASMIC score}} | ||
<br> | <br> | ||
'''<big>Risk of | '''<big>Risk of ADAMTS13 deficiency</big>''' '''<big>in adults with suspected TTP</big>''' '''<big>:</big>''' | ||
* '''Low-risk''' = 0 to 4 points | * '''Low-risk''' = 0 to 4 points | ||
* '''Intermediate risk''' = 5 points | * '''Intermediate risk''' = 5 points | ||
* '''High-risk''' = 6 to 7 points | * '''High-risk''' = 6 to 7 points | ||
==References== | ==References== | ||
<references /> | |||
Latest revision as of 00:12, 21 December 2018
|
Thrombotic thrombocytopenic purpura Microchapters |
|
Differentiating Thrombotic thrombocytopenic purpura from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Thrombotic thrombocytopenic purpura diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Thrombotic thrombocytopenic purpura diagnostic study of choice |
|
FDA on Thrombotic thrombocytopenic purpura diagnostic study of choice |
|
CDC on Thrombotic thrombocytopenic purpura diagnostic study of choice |
|
Thrombotic thrombocytopenic purpura diagnostic study of choice in the news |
|
Blogs on Thrombotic thrombocytopenic purpura diagnostic study of choice |
|
Directions to Hospitals Treating Thrombotic thrombocytopenic purpura |
|
Risk calculators and risk factors for Thrombotic thrombocytopenic purpura diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Saeedeh Kowsarnia M.D.[2],Sogand Goudarzi, MD [3]
Overview
Study of choice
- ADAMTS13 test:
Studies that may be considered for diagnosis of the suspected cases of TTP:
- Complete blood count (CBC) with platelet count
- Review of the peripheral blood smear
- Serum electrolytes and creatinine
- Serum lactate dehydrogenase (LDH)
- Serum bilirubin level
- Coagulation testing ( PT, aPTT, fibrinogen, D-dimer)
- Serum haptoglobin level
- Direct antiglobulin (Coombs) test (DAT)
- ADAMTS13 activity and inhibitor testing
- Stool exam
- Genetic testing for mutation in ADAMTS13 at the genomic level
- Antibodies to complement factors H and I for ruling out atypical hemolytic uremic syndrome
PLASMIC score
Risk of ADAMTS13 deficiency in adults with suspected TTP :
- Low-risk = 0 to 4 points
- Intermediate risk = 5 points
- High-risk = 6 to 7 points